… our Axiomer ™ platform and the continued preclinical and clinical development thereof, our patent estate, the … the cost, timing and results of preclinical studies and clinical trials and other development activities by us and … the global market; the likelihood of our preclinical and clinical programs being initiated and executed on timelines …
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will participate in the RNA Editing Summit, June 18-20, 2024, in Boston, Mas
… the cost, timing and results of preclinical studies and clinical trials and other development activities by us and … the global market; the likelihood of our preclinical and clinical programs being initiated and executed on timelines … timely enrollment of subjects and patients to advance our clinical trials and maintain their own operations; our …
… while we continue to analyze data from the Illuminate trial of sepofarsen and identify next steps for the program, … dystrophies and our product candidates, including the clinical development and the therapeutic potential thereof. … the cost, timing and results of preclinical studies and clinical trials and other development activities by us and …
… the cost, timing and results of preclinical studies and clinical trials and other development activities by us and … or halted by the COVID-19 pandemic; the likelihood of our clinical programs being executed on timelines provided and … timely enrollment of subjects and patients to advance our clinical trials and maintain their own operations; our …